Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -5.51 is 18% above its 5-year average of -6.70, near the high end of its 5-year range (-12.28–-2.89).
35.81% below its 12-month average of -4.06.
Reported quarterly EPS; no daily interpolation. Q1 FY2027 (2026-06-30): -0.89.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 20 comparable quarters.
EARNINGS PER SHARE (EPS)
-5.51
EARNINGS PER SHARE (EPS) AVG TTM
-4.06
EARNINGS PER SHARE (EPS) AVG 3Y
-4.55
EARNINGS PER SHARE (EPS) AVG 5Y
-6.70
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-35.81%
CURRENT VS 3Y AVG
-21.10%
CURRENT VS 5Y AVG
+17.80%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Helus Pharma Inc.
Market Cap
$666.95M
Earnings Per Share (EPS)
-5.51
TTM Avg
-4.06
3Y Avg
-4.55
5Y Avg
-6.70
Market Cap
$673.41M
Earnings Per Share (EPS)
0.04
TTM Avg
0.31
3Y Avg
0.21
5Y Avg
0.05
Market Cap
$660.29M
Earnings Per Share (EPS)
-1.16
TTM Avg
-1.18
3Y Avg
-1.68
5Y Avg
-2.29
Market Cap
$657.89M
Earnings Per Share (EPS)
-0.30
TTM Avg
-0.54
3Y Avg
-0.54
5Y Avg
-0.54
Market Cap
$656.59M
Earnings Per Share (EPS)
-2.72
TTM Avg
-2.70
3Y Avg
-2.77
5Y Avg
-2.61
Market Cap
$681.02M
Earnings Per Share (EPS)
-2.46
TTM Avg
-3.34
3Y Avg
-3.80
5Y Avg
-4.24
Market Cap
$681.27M
Earnings Per Share (EPS)
-1.91
TTM Avg
-2.52
3Y Avg
-4.99
5Y Avg
-9.27
Market Cap
$685.49M
Earnings Per Share (EPS)
-2.76
TTM Avg
-3.16
3Y Avg
-2.11
5Y Avg
-1.54
Market Cap
$691.79M
Earnings Per Share (EPS)
-2.13
TTM Avg
-2.04
3Y Avg
-2.21
5Y Avg
-1.87
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Helus Pharma Inc. (HELP) | $666.95M | -5.51 | -4.06 | -4.55 | -6.70 |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 0.04 | 0.31 | 0.21 | 0.05 |
| Annexon, Inc. (ANNX)vs › | $660.29M | -1.16 | -1.18 | -1.68 | -2.29 |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | -0.30 | -0.54 | -0.54 | -0.54 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | -2.72 | -2.70 | -2.77 | -2.61 |
| Verastem, Inc. (VSTM)vs › | $681.02M | -2.46 | -3.34 | -3.80 | -4.24 |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | -1.91 | -2.52 | -4.99 | -9.27 |
| Anteris Technologies Global Corp. (AVR)vs › | $685.49M | -2.76 | -3.16 | -2.11 | -1.54 |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $691.79M | -2.13 | -2.04 | -2.21 | -1.87 |
| Faeth Therapeutics, Inc. (FTH)vs › | $693.19M | -141.65 | -20.37 | -24.20 | -22.76 |
Trailing EPS (TTM)
$-5.51
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2026-03-31 | -4.23 |
| 2025-03-31 | -3.88 |
| 2024-03-31 | -2.89 |
| 2023-03-31 | -7.19 |
| 2022-03-31 | -12.28 |
| 2021-03-31 | -9.74 |
| 2020-03-31 | -1.05 |
| 2019-07-31 | -0.21 |
| 2018-07-31 | -0.53 |
| 2017-07-31 | -0.28 |
